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Abstract
We have cloned a cDNA encoding rabbit a adrenoceptor from the rabbit liver cDNA library. The deduced amino-acid1d
sequence of this clone encodes a protein of 576 amino acids that shows strong sequence homology to previously cloned
human, rat and mouse a adrenoceptors. The pharmacological radioligand binding properties of this clone expressed in1d
COS-7 cells were similar to those of rat a -adrenoceptors. Competitive RTrPCR assays revealed wide tissue distribution1d
of the a adrenoceptor mRNA in rabbit, especially abundant in vas deferens, aorta, prostate and cerebral cortex.1d
 .Keywords: a -Adrenoceptor; Gene cloning; Nucleotide sequence; Pharmacological characteristic; Tissue distribution; Rabbit1d
a -Adrenoceptors are widely distributed in many1
tissues, where they mediate a diversity of sympathetic
w xadrenergic responses 1,2 . However, the a -adreno-1
ceptors are not homogeneous; there is a great deal of
uncertainty regarding the kind and nature of the
a -adrenoceptors. Two distinct subtypes a and1 1A
.a were first demonstrated in the radioligand bind-1B
w xing studies 1,3 , but the presence of additional sub-
 .types a , a and a has been proposed in the1D 1L 1N
w xfollowing pharmacological studies 2,4–6 . There-
after, three receptors corresponding to the a , a1A 1B
and a subtypes have been cloned in molecular1D
) Corresponding author. Fax: q81 776 618130, E-mail: mura-
matu@fmsrsa.fukui-med.ac.jp
1 The nucleotide sequence reported in this paper has been
submitted to the GenBank under the accession number U64032.
w xbiological studies 2,7,8 , and the recombinant sub-
types are designated as a , a and a with1a 1b 1d
lowercase subscript letters, in contrast to the native
receptors with uppercase subscript letters mentioned
w xabove 9 . The a -adrenoceptor was originally cloned1d
w x w xby Lomasney et al. 10 and Perez et al. 11 . This
w xreceptor shows wide tissue distribution in mouse 12 ,
w x w xrat 10,11 and human 13 but the physiological roles
are still not clear, although predominant involvement
of a -adrenoceptor in the contractile response to1D
noradrenaline was more recently reported in the rat
w xthoracic aorta 14,15 . In the present study, we first
report the cloning, sequence, pharmacological charac-
teristics and tissue distribution of rabbit a -adreno-1d
ceptor.
We have constructed a rabbit liver cDNA library
in lZAP II vector and screened it with a 333 bp
0005-2736r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0005-2736 96 00229-5
( )F. Suzuki et al.rBiochimica et Biophysica Acta 1323 1997 6–11 7
DNA fragment of bovine a -adrenoceptor gene la-1a
beled by nick-translation as a probe. The 333 bp
fragment was PCR amplified from bovine cortex
cDNA with a pair of primers; 5X-TTC TGC AAT
GTC TGG GCG GCG-3X and 5X-GTA GAC CCG
GCA GTA CAT GAC-3X coding for the third to fifth
w xtransmembrane domains 16 . After isolating a posi-
tive plaque, the inserted DNA fragment was sub-
cloned into pBluescript according to the manufac-
 .turer’s instruction Stratagene and the nucleotide
sequence was determined using overlapping tem-
plates by the dideoxy chain termination method with
the ABI 373A DNA sequencer. Then, the clone was
ligated into a mammalian expression vector pSI Pro-
Fig. 1. Nucleotide and deduced amino-acid sequence of rabbit a adrenoceptor. Deduced membrane-spanning segments TM I–TM VII1d
are underlined.
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. mega and transfected into COS-7 cells RIKEN Cell
.Bank by the DEAE-dextran method. As controls,
human a , hamster a and rat a adrenoceptor1a 1b 1d
w xclones were also transfected 17 . Cells were har-
vested 72 h after transfection, homogenized and cen-
trifuged at 80 000=g for 30 min at 48C. The result-
ing pellet was resuspended in the assay buffer 50
.mM Tris-HCl, 1 mM EDTA, pH 7.4 and used for
w xthe binding assays, as described previously 18 .
w3 x  .H YM617 tamsulocin, NEN was used as a radioli-
gand for a -adrenoceptor binding, and nonspecific1
binding was defined under the presence of 0.3 mM
prazosin in the reaction.
Tissue distribution of rabbit a -mRNA was ex-1d
amined with competitive RT-PCR assays. Briefly,
w xafter extraction of total cellular RNA 19 , the RNA
 .was treated with RNase-free DNase I Pharmacia for
30 min at 378C and was extracted again. The com-
petitor RNA was transcribed with T7 RNA poly-
 .merase Gibco BRL from a template DNA which
was constructed by inserting a 60 bp SmaIrRsaI
fragment of pBluescript DNA into MscI site of rabbit
 .a clone at 1066 base, see Fig. 1 . The sample1d
 .RNA 250 ng was mixed with the competitor RNA
 .30 pg and were reverse transcribed with Tth poly-
 .merase Perkin Elmer using an antisense primer
 X X5 -GGG TAG ATG AGT GGG TTC AC-3 , 1223–
.1204 base at 708C for 15 min. The resulting cDNA
was amplified in Programmable Thermal Controller
 .PTC-100 MJ Research with Pwo DNA polymerase
 .  .  . w xFig. 2. Comparison of amino-acid sequences of the rabbit U64032 , human L31772 , rat L31771 and mouse 14 a adrenoceptors.1d
Identical amino acids are substituted with dots, and gaps in the sequences are indicated with horizontal bars.
( )F. Suzuki et al.rBiochimica et Biophysica Acta 1323 1997 6–11 9
Table 1
Pharmacological characteristics of rabbit a - and other a -adrenoceptors expressed in COS-7 cells1d 1
Drug pK i
rabbit a rat a human a hamster a1d 1d 1a 1b
Prazosin 9.15"0.03 9.94"0.04 9.71"0.07 10.32"0.05
WB4101 8.75"0.03 9.61"0.01 9.74"0.02 8.74"0.03
5-Methylurapidil 7.33"0.13 7.88"0.05 8.78"0.03 7.34"0.03
JTH-601 8.39"0.05 8.97"0.06 9.85"0.04 9.17"0.10
BMY7378 8.60"0.05 9.05"0.03 7.01"0.05 7.29"0.02
HV723 8.62"0.06 8.94"0.02 8.97"0.01 8.80"0.08
Rauwolscine -6 -6 -6 -6
Propranolol -5 -5 -5 -5
Noradrenaline 7.19"0.06 7.12"0.04 5.77"0.04 5.90"0.02
Oxymetazoline 5.96"0.07 6.16"0.04 8.03"0.01 6.52"0.04
correlation coefficient – 0.98 0.60 0.82
w3 xConcentrations of H YM617 used were 200 pM, 100 pM, 70 pM and 500 pM for rabbit a , rat a , human a and hamster a1d 1d 1a 1b
adrenoceptors, respectively.
Data shown are mean"standard error of 3–5 experiments.
pK : negative log of the equilibrium dissociation constant for each drug.i
 .correlation coefficient: correlation between the affinities for tested drugs except rauwolscine and propranolol of rabbit a subtype and1d
the other subtypes.
 .Boehringer employing a primer set of a sense primer
 X X5 -CTC CGT GCG CCT GCT CAA GT-3 , 1104–
.1033 base and the antisense primer in the following
condition; initial denaturation at 958C for 2 min, 35
cycles of denaturation at 958C for 30 sec, annealing
at 608C for 30 sec and extension at 728C for 30 sec
and a final extension at 728C for 4 min. PCR product
was separated in 6% polyacrylamide gel elec-
trophoresis and was stained with ethidium bromide.
The intensity of the product band was quantified
 .under UV light using Densitograph System ATTO .
A single positive clone having a DNA insert of 2.6
kbp was isolated from the analysis of 3=105 recom-
binants. The nucleotide sequence of the cDNA clone
 .Fig. 1 contained an open reading frame of 1731 bp
encoding a 576-amino-acid peptide. The amino-acid
w xsequence had 84, 79 and 89% identity with rat 10,11 ,
w x w xmouse 12 and human 13 a -adrenoceptors, re-1d
 .spectively Fig. 2 . The homologues of a -adreno-1d
ceptor including this rabbit clone share high homol-
ogy not only in the membrane spanning region but
also in amino and carboxyl termini including two
 .asparagine residues 70 and 87 residues that could
serve as N-glycosylation target. However, the homol-
ogy of the amino-acid sequences between this rabbit
clone and homologues of a and a subtypes was1a 1b
recognized only in the membrane spanning region
and was less than 60%. We concluded that this clone
encodes a rabbit a -adrenoceptor. The result of1d
sequence comparison suggests that a -specific char-1d
Fig. 3. Competitive RT-PCR analysis of a -adrenoceptor mRNA from rabbit, various tissues. Total RNA from rabbit tissues were mixed1d
with competitor RNA and were reverse transcribed, PCR amplified and separated in electrophoresis as described in the text. The product
 .  .from tissue RNA 210 bp and that from competitor RNA 270 bp are indicated by arrows on the left. Analyzed rabbit tissues are heart,
kidney, liver, lung, spleen, skeletal muscle, aorta, cerebellum, hippocampus, brain stem, cerebral cortex, thalamus, vas deferens, prostate,
submaxillary gland and parotid gland, from lanes 1 to 16, respectively. The f X174 DNArHaeIII marker was run in lane 17.
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Table 2
Distribution of a -adrenoceptor mRNA in rabbit tissues1d
Tissue Relative level
Heart 0.3"0.2
Kidney 0.6"0.0
Liver -0.1
Lung 2.5"0.1
Spleen 0.5"0.0
Skeletal muscle -0.1
Thoracic aorta 5.2"0.9
Cerebellum 1
Hippocampus 0.4"0.1
Brain stem 0.8"0.3
Cerebral cortex 3.1"0.7
Thalamus 0.4"0.1
Vas deferens 5.6"2.1
Prostate 4.2"1.2
Submaxillary gland -0.1
Parotid gland -0.1
Relative levels of expression of a -adrenoceptor mRNA in1d
various tissues were listed using the level of that in cerebellum as
1.
Values in the table represent mean"standard error of three
independent experiments.
acter depends not only on the membrane spanning
region but on the extracellular as well as the intra-
cellular tails.
Transfection of COS7 cells with the cDNA clones
of rabbit a and other a -adrenoceptors resulted in1d 1
w3 xspecific binding of the H YM617. Analysis of satu-
w3 xration binding data for H YM617 resulted in a
single dissociation constant, pK s 9.73 " 0.05,D
10.17"0.01, 10.63"0.04 and 9.45"0.06 for rabbit
a , rat a , human a and hamster a adrenocep-1d 1d 1a 1b
tors, respectively. The pharmacological binding pro-
file of rabbit a -adrenoceptor was characteristic of1d
 .that expected for an a subtype Table 1 . Espe-1d
w xcially, BMY7378, an a -selective antagonist 20 ,1d
and noradrenaline showed higher affinity for the
a -subtypes than for a and a subtypes. This1d 1a 1b
pharmacological analysis also supported our conclu-
sion above based on the peptide sequence.
In the competitive RTrPCR assay used, we con-
firmed linear relationship between the ratios of am-
plified target and competitor signals changing the
competitor doses from 3 pg to 100 pg data not
.shown . This range of linearity is compatible with
w xother reports 21–23 . The representative results of
competitive RTrPCR for rabbit tissues are shown in
Fig. 3. The a -adrenoceptor mRNA was expressed1d
most abundantly in the rabbit vas deferens, prostate,
 .aorta and cerebral cortex Table 2 . This distribution
w xpattern was consistent with those in rat 10,11,22 ,
w x w xhuman 13,23 and mouse 12 . Since the physio-
logical roles of a -adrenoceptor are little known1d
except the functional involvement in noradrenaline-
w xinduced contraction of rat aorta 14,15 , the result
presented here would be an important clue to uncover
its biological functions.
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